The pending class action lawsuit alleges that Capricor Therapeutics misled shareholders regarding its clinical trial data for Deramiocel, a cell therapy intended for Duchenne muscular dystrophy. According to the complaint, the company allegedly altered its pre-specified statistical analysis plan without securing prior FDA approval before resubmitting its Biologics License Application. These omissions reportedly created significant risks regarding the therapy's regulatory approval and clinical effectiveness, leading to shareholder losses once the information surfaced.
Capricor Therapeutics Investors Face September 28 Deadline in Lawsuit
Investors who incurred losses exceeding $100,000 in Capricor Therapeutics, Inc. securities between December 17, 2025, and July 26, 2026, face a critical deadline. September 28, 2026, marks the final opportunity for those who purchased the company's stock during this period to petition the court to serve as lead plaintiff.
Investors are not required to act as lead plaintiff to participate in a potential recovery, and no class has been certified at this time. Those who purchased securities during the defined class period may seek representation through counsel of their choice. The Rosen Law Firm, which filed the action, is currently accepting inquiries from affected investors. Participation in the litigation involves no out-of-pocket fees or costs, as legal representation operates on a contingency fee basis.
Comments (0)
No comments yet. Be the first!